Targeting Interleukin-6 Signaling in Clinic.
By Sujin Kang, Toshio Tanaka, M. Narazaki, T. Kishimoto. Immunity, 2019
744 citations recorded by the source corpus.
Interleukin-6 (IL-6) is a pleiotropic cytokine with roles in immunity, tissue regeneration, and metabolism. Rapid production of IL-6 contributes to host defense during infection and tissue injury, but excessive synthesis of IL-6 and dysregulation of IL-6 receptor signaling is involved in disease pathology. Therapeutic agents targeting the IL-6 axis are effective in rheumatoid arthritis, and applications are being extended to other settings of acute and chronic inflammation. Recent studies reveal that selective blockade of different modes of IL-6 receptor signaling has different outcomes on disease pathology, suggesting novel strategies for therapeutic intervention. However, some inflammatory diseases do not seem to respond to IL-6 blockade. Here, we review the current state of IL-6-targeting approaches in the clinic and discuss how to apply the growing understanding of the immunobiology of IL-6 to clinical decisions.
Subfields: Hematology, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/19ebc6722d08bc09565f4249cb990c99bccbac39
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
Citations in the corpus
- Aging in COVID-19: Vulnerability, immunity and intervention (2020, positive): “and anti-IL-6R MAbs can all antagonize IL-6 cis signaling (via canonical membrane-bound IL-6Rα and gp130) and trans signaling (via soluble IL-6R), but only anti-IL-6R MAbs can antagonize IL-6 trans presentation, a newly described mode of IL-6 signaling that involves membrane-bound IL-6Rα of dendriti”